Trials / Completed
CompletedNCT03502876
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL): Analysis of Real-life Data: "Snapshot" at 3 Years From the End of Ibrutinib ATU. A National Study of the FILO-LLC Group
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 198 (actual)
- Sponsor
- French Innovative Leukemia Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Assessment of the mutational profile of the residual clone and the distribution of lymphocyte subpopulations at 3 years of treatment with ibrutinib This project has an epidemiological part: to establish the percentage of patients, in a real-life situation, still undergoing treatment 3 years after its initiation, as well as a biological part: to determine the evolution of the clone and the prevalence of BTK mutations and PLCg2 in the absence of clinical or biological criteria for scalability.
Detailed description
Observationnal and biological study
Conditions
Timeline
- Start date
- 2017-11-02
- Primary completion
- 2018-12-31
- Completion
- 2019-12-31
- First posted
- 2018-04-19
- Last updated
- 2020-05-18
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03502876. Inclusion in this directory is not an endorsement.